TY - JOUR
T1 - Key phosphorylation sites in GPCRs orchestrate the contribution of β-Arrestin 1 in ERK1/2 activation
AU - Baidya, Mithu
AU - Kumari, Punita
AU - Dwivedi-Agnihotri, Hemlata
AU - Pandey, Shubhi
AU - Chaturvedi, Madhu
AU - Stepniewski, Tomasz Maciej
AU - Kawakami, Kouki
AU - Cao, Yubo
AU - Laporte, Stéphane A.
AU - Selent, Jana
AU - Inoue, Asuka
AU - Shukla, Arun K.
N1 - Funding Information:
Research in AKS's laboratory is supported by the Intermediate Fellowship of the Wellcome Trust/DBT India Alliance (IA/I/14/1/501285) awarded to AKS, Department of Biotechnology (DBT) (BT/PR29041/BRB/10/1697/20), Science and Engineering Research Board (EMR/2017/003804), Young Scientist Award from the Lady TATA Memorial Trust, Department of Science and Technology (DST/SJF/LSA‐03/2017‐18), and the Indian Institute of Technology, Kanpur. AKS is an Intermediate Fellow of Wellcome Trust/DBT India Alliance (IA/I/14/1/501285), EMBO Young Investigator and Joy Gill Chair Professor. MB is supported by the National Post‐Doctoral Fellowship of SERB (PDF/2016/002930) and Institute Post‐Doctoral Fellowship of IIT Kanpur. HD‐A is supported by National Post‐Doctoral Fellowship of SERB (PDF/2016/2893) and BioCare grant from DBT (BT/PR31791/BIC/101/1228/2019). MC is supported by CSIR (Council for Scientific and Industrial Research) fellowship (09/092(0976)/2017‐EMR‐I). We thank Dr. Eshan Ghosh for helping in ERK1/2 activation assay. JS's laboratory acknowledges support from the Instituto de Salud Carlos III FEDER (PI15/00460 and PI18/00094) and the ERA‐NET NEURON & Ministry of Economy, Industry and Competitiveness (AC18/00030). TMS acknowledges support from Nacional Center of Science, Poland grant 2017/27/N/NZ2/02571. This work was also supported by a grant from the Canadian Institutes of Health Research (CIHR) (MOP‐74603) to SAL, and YC is supported by a doctoral training scholarship from the Fonds de recherche santé Québec. We thank Kayo Sato, Shigeko Nakano, and Ayumi Inoue (Tohoku University) for their assistance of plasmid preparation and cell‐based GPCR assays. AI was funded by the PRIME JP19gm5910013 and the LEAP JP19gm0010004 from the Japan Agency for Medical Research and Development (AMED) and the Japan Society for the Promotion of Science (JSPS) KAKENHI 17K08264. KK received a Grant‐in‐Aid for JSPS Fellows 19J11256.
Funding Information:
Research in AKS's laboratory is supported by the Intermediate Fellowship of the Wellcome Trust/DBT India Alliance (IA/I/14/1/501285) awarded to AKS, Department of Biotechnology (DBT) (BT/PR29041/BRB/10/1697/20), Science and Engineering Research Board (EMR/2017/003804), Young Scientist Award from the Lady TATA Memorial Trust, Department of Science and Technology (DST/SJF/LSA-03/2017-18), and the Indian Institute of Technology, Kanpur. AKS is an Intermediate Fellow of Wellcome Trust/DBT India Alliance (IA/I/14/1/501285), EMBO Young Investigator and Joy Gill Chair Professor. MB is supported by the National Post-Doctoral Fellowship of SERB (PDF/2016/002930) and Institute Post-Doctoral Fellowship of IIT Kanpur. HD-A is supported by National Post-Doctoral Fellowship of SERB (PDF/2016/2893) and BioCare grant from DBT (BT/PR31791/BIC/101/1228/2019). MC is supported by CSIR (Council for Scientific and Industrial Research) fellowship (09/092(0976)/2017-EMR-I). We thank Dr. Eshan Ghosh for helping in ERK1/2 activation assay. JS's laboratory acknowledges support from the Instituto de Salud Carlos III FEDER (PI15/00460 and PI18/00094) and the ERA-NET NEURON & Ministry of Economy, Industry and Competitiveness (AC18/00030). TMS acknowledges support from Nacional Center of Science, Poland grant 2017/27/N/NZ2/02571. This work was also supported by a grant from the Canadian Institutes of Health Research (CIHR) (MOP-74603) to SAL, and YC is supported by a doctoral training scholarship from the Fonds de recherche santé Québec. We thank Kayo Sato, Shigeko Nakano, and Ayumi Inoue (Tohoku University) for their assistance of plasmid preparation and cell-based GPCR assays. AI was funded by the PRIME JP19gm5910013 and the LEAP JP19gm0010004 from the Japan Agency for Medical Research and Development (AMED) and the Japan Society for the Promotion of Science (JSPS) KAKENHI 17K08264. KK received a Grant-in-Aid for JSPS Fellows 19J11256.
Publisher Copyright:
© 2020 The Authors
PY - 2020/9/3
Y1 - 2020/9/3
N2 - β-arrestins (βarrs) are key regulators of G protein-coupled receptor (GPCR) signaling and trafficking, and their knockdown typically leads to a decrease in agonist-induced ERK1/2 MAP kinase activation. Interestingly, for some GPCRs, knockdown of βarr1 augments agonist-induced ERK1/2 phosphorylation although a mechanistic basis for this intriguing phenomenon is unclear. Here, we use selected GPCRs to explore a possible correlation between the spatial positioning of receptor phosphorylation sites and the contribution of βarr1 in ERK1/2 activation. We discover that engineering a spatially positioned double-phosphorylation-site cluster in the bradykinin receptor (B2R), analogous to that present in the vasopressin receptor (V2R), reverses the contribution of βarr1 in ERK1/2 activation from inhibitory to promotive. An intrabody sensor suggests a conformational mechanism for this role reversal of βarr1, and molecular dynamics simulation reveals a bifurcated salt bridge between this double-phosphorylation site cluster and Lys294 in the lariat loop of βarr1, which directs the orientation of the lariat loop. Our findings provide novel insights into the opposite roles of βarr1 in ERK1/2 activation for different GPCRs with a direct relevance to biased agonism and novel therapeutics.
AB - β-arrestins (βarrs) are key regulators of G protein-coupled receptor (GPCR) signaling and trafficking, and their knockdown typically leads to a decrease in agonist-induced ERK1/2 MAP kinase activation. Interestingly, for some GPCRs, knockdown of βarr1 augments agonist-induced ERK1/2 phosphorylation although a mechanistic basis for this intriguing phenomenon is unclear. Here, we use selected GPCRs to explore a possible correlation between the spatial positioning of receptor phosphorylation sites and the contribution of βarr1 in ERK1/2 activation. We discover that engineering a spatially positioned double-phosphorylation-site cluster in the bradykinin receptor (B2R), analogous to that present in the vasopressin receptor (V2R), reverses the contribution of βarr1 in ERK1/2 activation from inhibitory to promotive. An intrabody sensor suggests a conformational mechanism for this role reversal of βarr1, and molecular dynamics simulation reveals a bifurcated salt bridge between this double-phosphorylation site cluster and Lys294 in the lariat loop of βarr1, which directs the orientation of the lariat loop. Our findings provide novel insights into the opposite roles of βarr1 in ERK1/2 activation for different GPCRs with a direct relevance to biased agonism and novel therapeutics.
KW - ERK1/2 MAP kinase
KW - G protein-coupled receptors
KW - biased agonism
KW - cellular signaling
KW - β-arrestins
UR - http://www.scopus.com/inward/record.url?scp=85088445752&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088445752&partnerID=8YFLogxK
U2 - 10.15252/embr.201949886
DO - 10.15252/embr.201949886
M3 - Article
C2 - 32715625
AN - SCOPUS:85088445752
VL - 21
JO - EMBO Reports
JF - EMBO Reports
SN - 1469-221X
IS - 9
M1 - e49886
ER -